

# Substantia Nigra MRI markers are lower in Alzheimer's disease and are linked to novelty and memory

Friedrich Krohn<sup>1</sup>, Mousumi Sarkar<sup>1</sup>, Hartmut Schütze<sup>1</sup>, Panagiotis Iliopoulos<sup>1</sup>, Lucía Penalba-Sánchez<sup>1,2</sup>, Dorothea Hämmerer<sup>1,2</sup>, Renat Yakupov<sup>1,2</sup>, Falk Lüsebrink<sup>1</sup>, Annika Spottke<sup>3</sup>, Anja Schneider<sup>3,4</sup>, Nina Roy<sup>3,4</sup>, Enise I. Incesoy<sup>1,2,5</sup>, Michael Heneka<sup>3,6</sup>, Ingo Kilimann<sup>7</sup>, Luca Kleineidam<sup>3,4</sup>, Stefan J Teipel<sup>7</sup>, Frederic Brosseron<sup>3</sup>, Doreen Goerss<sup>3,4</sup>, Wenzel Glanz<sup>1,2</sup>, Matthias Schmid<sup>8</sup>, Ayda Rostamzadeh<sup>9</sup>, Michael Wagner<sup>3,4</sup>, Klaus Fliessbach<sup>3,4</sup>, Frank Jessen<sup>10</sup>, Emrah Düzel<sup>1,2</sup>, Matthew Betts<sup>1,2</sup>

## Author affiliations:

1 Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, 39120 Magdeburg, Germany

2 German Center for Neurodegenerative Diseases, 39120 Magdeburg, Germany

3 German Center for Neurodegenerative Diseases, 53127 Bonn, Germany

4 Dept. of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn, Bonn, Germany

5 Department for Psychiatry and Psychotherapy, University Clinic Magdeburg, Magdeburg, Germany

6 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4367 Belvaux

7 German Center for Neurodegenerative Diseases, 18147 Rostock, Germany

8 Institute for Medical Biometry, Informatics and Epidemiology, Medical Faculty, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany

9 Department of Psychiatry, University of Cologne, Medical Faculty, Kerpener Strasse 62, 50924 Cologne, Germany

10 University of Cologne, Faculty of Medicine, 50932 Cologne, Germany

Correspondence to: Friedrich Krohn

Institute für kognitive Neurologie und Demenzforschung, Magdeburg, Germany

Krohn.friedrich@dzne.de

**Keywords:** Substantia Nigra (SN), Alzheimer's disease, neuromelanin, memory, novelty

**Abbreviations:**

SN= Substantia Nigra, HC=Healthy Control, SCD=Subject cognitive decline, MCI=Mild cognitive impairment, ADD=clinically defined dementia due to Alzheimer's disease

## Abstract

Individuals with Alzheimer's disease dementia (ADD) show Alzheimer's disease (AD) pathology in and heterogeneous degeneration of the Substantia Nigra (SN) postmortem. However, it is unclear how the SN degeneration is related to cognitive dysfunction across the ADD continuum. In this study, using data from a prospective dementia study (DELCODE), we investigated if in-vivo SN MRI measures are lower in cases with clinically defined ADD than in healthy control subjects (HC) and associated with functional activity during the processing of novel visual stimuli and subsequent recognition memory.

161 DELCODE participants (69 years  $\pm$ 6 years, 88 men), including 79 Healthy Controls, 71 individuals with subjective cognitive impairment (SCD), 17 individuals with mild cognitive impairment (MCI), and 10 individuals with ADD, completed a scene novelty and encoding task and a 3T neuromelanin (NM)-sensitive MRI scan, from which in-vivo measures of SN MRI contrast and SN volume were calculated. For 71 individuals, CSF levels of phosphoTau, total tau, and amyloid beta 42/40 ratio (A $\beta$ 42/40) were available. All individuals completed a neuropsychological task battery from which a global cognitive score was calculated.

SN volume but not SN MRI contrast was lower in individuals with clinical ADD (One-way ANOVA:  $F(3,156)=4.13$ ,  $N=160$ ,  $p=0.0056$ , Tukey posthoc test:  $p=0.003$ ) and SN MRI contrast and volume were not associated with A $\beta$ 42/40, ptau, and ttau CSF levels (all  $p<0.1$ ). SN MRI contrast was positively associated with anterior hippocampal functional activity during the presentation of novel stimuli in individuals with A $\beta$ 42/40 ratio levels

below a pathological threshold of 0.08 (A $\beta$ 42/40 positive, (p(FWE)=0.002, 157 voxels, n=28) but not in A $\beta$ 42/40 negative individuals. Moreover, SN volume was positively associated with recognition memory (N=160, p=0.017, r<sup>2</sup>=0.11) and global cognition (p<0.0001, N=160, r<sup>2</sup>=0.221) across the ADD continuum.

Our study emphasizes the potential of using in-vivo SN MRI markers to understand the impact of AD pathology-independent SN degeneration on recognition memory and novelty processing dysfunction in ADD. Our results motivate future longitudinal studies exploring how SN volume and SN contrast change over time, how these differentially associate with cognitive decline and how the SN volume and SN contrast might be associated with other dopamine-dependent cognitive functions.

## 1 Introduction

The substantia nigra (SN), a central dopaminergic region, is involved in various functions, including movement initiation,<sup>1</sup> executive function,<sup>2</sup> working memory,<sup>3</sup> long-term memory<sup>4</sup> and novelty processing.<sup>5</sup> Indeed, the SN and the surrounding Ventral Tegmental Area (VTA) cells show increased fMRI and cellular activity when individuals are presented with novel stimuli<sup>5-7</sup>. Dopaminergic hippocampal novelty signals facilitate information encoding into long-term memory.<sup>8-11</sup> Therefore, the SN might be linked to novelty-related memory formation.

Different SN MRI contrasts and SN volume have been assessed non-invasively in vivo using neuromelanin (NM)-sensitive MRI<sup>4,12-15</sup> owing to the SN's high levels of NM, a dark iron-rich<sup>16</sup> that has been shown to correlate with SN MRI contrast.<sup>12</sup> In older adults, SN MRI contrast and volume measures have been linked to memory and cognitive control<sup>4,17,18</sup>. SN MRI measures are sensitive to volumetric<sup>15</sup> and SN MRI contrast<sup>19</sup> decrease and working memory decline<sup>14</sup> in Parkinson's disease.

While the role of the SN has been extensively studied in aging, its role in AD is underexplored. AD is a neurodegenerative disease characterized by the presence of pathological  $\beta$  amyloid and hyperphosphorylated tau.<sup>20,21</sup> A meta-analysis showed lower dopamine levels and D1 and D2 receptor density,<sup>22</sup> indicating that the dopaminergic system is

affected in AD. Also, SN volume and dopaminergic functions are affected by AD: Post-mortem cases show that SN volumetric reduction in clinically defined dementia due to Alzheimer's disease (ADD) is mild on average<sup>23–25</sup> but more pronounced than healthy aging<sup>23</sup>. Postmortem studies indicate that SN volume in ADD is highly variable across individuals—some show little to no degeneration.<sup>26</sup> In contrast, others show comparable degeneration to individuals with Parkinson's disease in a subset of individuals<sup>24,27</sup> and increasing volumetric cell loss with increasing AD dementia status.<sup>27</sup> Moreover, tau and amyloid pathology has been shown in SN cells in 60-91% of cases with ADD<sup>23,25,27–30</sup> and insoluble tau tangle levels are increased postmortem inside the SN at advanced stages of AD.<sup>27</sup>

Individuals with ADD show both behavioral<sup>31</sup> and hippocampal activation<sup>32</sup> deficits during novelty processing and do not show enhanced memory for novel compared to familiar events.<sup>33,34</sup> While postmortem studies show that the SN is affected in ADD, to our knowledge, no studies have investigated how SN degeneration is related to novelty and long-term memory deficits in ADD. Here, to assess the role of the SN in deficits in dopaminergic dysfunctions in ADD, using data from the prospective DZNE – Longitudinal Cognitive Impairment and Dementia Study (DELCODE), we assess the relationship between in-vivo SN MRI measures, novelty processing, and recognition memory using a combination of NM-sensitive MRI and task fMRI in individuals spanning the ADD continuum. We also investigate how SN MRI contrast and volume are affected by AD pathology in a subset of individuals with available CSF biomarker levels. Finally, we investigate whether the relationship between SN volume and contrast, novelty processing, and memory is influenced by CSF biomarkers of AD pathology load.

## 2 Method

### 2.1 Subjects

Our dataset is a subset from the multicenter DELCODE study (Jessen et al., 2018) containing 160 subjects (72 men, 69±6 years) made up of 79 healthy controls (HC), 55 participants with

subjective cognitive decline (SCD), 17 participants with mild cognitive impairment (MCI), and 10 individuals diagnosed with ADD (for participant statistics see table 1). All participants were older than 60, fluent in German, and provided informed consent. HC were recruited through local advertisements, while SCDs, MCIs, and ADDs were recruited through (self) referrals. All subjects performing within 1.5 SD on subtests of the CERAD (Consortium to Establish a Registry of Alzheimer's disease) and not complaining about memory problems were considered healthy elderly individuals (HC). Subjects performing within the age- sex- and years of education-adjusted healthy range of 1.5 SD on CERAD but complaining of memory problems to physicians in memory clinics were regarded as individuals with SCD per recent guidelines.<sup>35</sup> Subjects performing below 1.5 SD on the age- sex- and years of education-adjusted delayed recall CERAD task and complaining of memory problems to physicians in memory clinics and had intact daily functioning were classified as individuals with MCI per recent guidelines.<sup>36</sup> Finally, subjects who fulfilled the clinical criteria for ADD according to current standards<sup>37</sup> were classified as individuals with ADD. Individuals performing below 18 points on the MMSE were excluded. For exclusion criteria and further DELCODE study details, see<sup>38</sup> The Institutional Review Boards of all participating study centers of the DZNE approved the study. All participants gave written informed consent before inclusion in the study. DELCODE is retrospectively registered at the German Clinical Trials Register (DRKS00007966) (04/05/2015). Data handling and quality control are reported elsewhere.<sup>38</sup>

## 2.2 Structural MRI scans

MRI data for the present study were acquired with Siemens scanners (Verio, Skyra systems) at the study centers in Berlin, Bonn, Magdeburg, and Rostock. For the analyses reported here, T1-weighted MPRAGE [3D GRAPPA PAT 2, 1mm<sup>3</sup> isotropic, 256 x 256 px, 192 slices, sagittal, 5min, repetition time (TR) 2500 ms, echo time (TE) 4.33 ms, inversion time (TI) 110 ms, flip angle (FA) 7°] images were used. Whole brain T1-weighted fast low-angle shot (FLASH) NM-sensitive MRI images were acquired using the following parameters: 0.75 x 0.75 x 0.75 mm<sup>3</sup> voxel size, 320 x 320 x 192 matrix, 5.56ms echo time, 20ms repetition time,

---

23° flip angle, 130 Hz/pixel bandwidth, 7/ 8 partial Fourier, and 13:50 min scan duration, as previously reported.<sup>39</sup>

## **2.3 Novelty task**

Participants first performed a previously published<sup>40</sup> and adapted<sup>41</sup> fMRI novelty (Fig. 1 A) and a recognition memory test. During the novelty part (Fig 1 A), inside the fMRI scanner, participants labeled two pre-familiarized images of scenes interleaved with 88 novel images of scenes as indoor or outdoor. Stimuli were shown as 8-bit gray-scale images scaled to 1250x750 pixel resolution and matched for luminance; the viewing horizontal half angle was 10.05° ('Presentation' software by Neurobehavioral Systems Inc.). All participants underwent vision correction with MR-compatible goggles according to standard operating procedures. All sites used the same 30" MR-compatible LCD screen, matched for distance, luminance, color, and contrast across sites and the same response buttons. Stimuli were shown for 2500 ms each. fMRI images were recorded using the following parameters: 3.5mm isotropic resolution, isotropic, 64 x 64 px, 47 slices, oblique axial/AC-PC aligned, 9 min, TR 2580 ms, TE 30 ms, FA 80, 206 volumes. The novelty part took around 11 min. A recognition memory part was then performed in front of a PC 70 min after the fMRI task: Participants rated the 88 recently presented scenes and 40 additional images on a 5-scale familiarity scale, with 1 indicating they were sure they did not see the image, 3 indicating they are not sure if saw the image, and 5 indicating they were sure they previously saw the image.

## **2.4 fMRI preprocessing**

First-level general linear models were calculated after preprocessing (slice time correction, unwarping, realignment, and spatial smoothing (isotropic Gaussian kernel of FWHM 6 x 6 x 6mm) using Statistical Parametric Mapping (SPM), Version 12) in native space (including six motion regressors from the realignment process). We used a hemodynamic response function with a 128-s high-pass filter, no global scaling, and no serial correlations modeled. The novelty contrast was calculated as the difference between activation in response to novel and activation in response to familiar images.

## 2.5 Group-level analyses

Using the Advanced Normalization Tools toolbox,<sup>42</sup> a study-specific group template was calculated from T1-weighted MPRAGE images. Four rigid-then-affine iterations and six runs of a non-linear multiresolution routine ensured stable convergence (three resolutions, maximum of 90 iterations, template update step size of 0.1 mm). Individual native space novelty contrasts were warped to the group template space using the Advanced Normalization Tools toolbox function `antsregistrationSyn`. Voxelwise mass-univariate associations between structural SN MRI measures and hippocampal fMRI novelty activation were later performed in this space. Hippocampal masks were derived from the Desikan-Killiany atlas<sup>43</sup> in FreeSurfer 6.0 ([surfer.nmr.mgh.harvard.edu/](http://surfer.nmr.mgh.harvard.edu/)). The FLASH images were upsampled to 0.375mm isotropic resolution using a MATLAB sinc function. Afterward, a study-specific template was generated from the FLASH images using the Advanced Normalization Tools toolbox (Fig 1B). In this template, the SN and a pons reference region (Fig 1C) were manually segmented using ITKSnap, and the segmented SN and pons were morphed back into the native space of all subjects. All masks were manually checked by expert raters (MS, MB). The SN MRI contrast was calculated as the ratio between the median intensity (*int*) inside the SN mask and the median *int* in the pons reference region as previously described<sup>39</sup> using the following formula:

$$\frac{(\text{Int}_{\text{SN}} - \text{Int}_{\text{Pons}})}{\text{Int}_{\text{Pons}}}$$

SN volume was calculated using FSLmaths. We here use bilateral values as the sum between left and right. Manual and semiautomatic segmentations of 24 younger individuals and 43 individuals were generated by MB and MS as previously described<sup>39</sup> and their volume and SN contrast were calculated. For this dataset, the dice scores of the volume were  $0.66 \pm 0.15$ , the ICC for the volume was 0.04 and the ICC for the SN contrast was 0.79. The ICC was so low because, compared to the manual segmentations, the semiautomated segmentations tended to overestimate the SN shown by high sensitivity of  $93 \pm 5\%$  and a low specificity of  $35 \pm 13\%$ .

-----Figure 1 approximately here-----

## 2.6 Cognitive Measures

Subjects were tested with extensive neuropsychological test batteries spanning verbal, memory, attentional, language, and visual domains.<sup>44</sup> Please refer to<sup>44</sup> for a detailed list of the applied batteries and tasks. Using confirmatory factor analysis in Mplus, five cognitive domain scores were derived from the task batteries: language, memory, executive function, visuospatial abilities, and working memory, and a global cognitive score was calculated as previously described from the five cognitive scores.<sup>44</sup>

## 2.7 CSF measures

For 71 participants of our dataset, CSF levels of AD biomarkers  $A\beta_{42/40}$  ratio, p-tau-181, and t-tau levels were measured. In adherence with recent guidelines in the ATN framework,<sup>21</sup> we thus estimated the  $A\beta_{42/40}$  ratio, tau pathology (p-tau-181), and neurodegeneration (total tau). The CSF levels were obtained centrally in Bonn using commercially available kits according to vendor specifications: V-PLEX Ab Peptide Panel 1 (6E10) Kit (K15200E) and V-PLEX Human Total Tau Kit (K151LAE) (Meso, MD, USA) and Innotech Phospho-Tau(181P) (81581; Fujirebio Germany GmbH, Hannover, Germany) as described previously.<sup>38</sup> We binarized the subjects into pathology positive/negative (i.e.,  $A\beta_{42/40}$  ratio smaller than 0.08 as  $A\beta_{42/40}$  positive, subjects with total tau levels greater than 510.9 pg/ml as tau positive, and subjects with levels greater than 73.65 pg/ml as phosphotau 181 positive) and vice versa according to recent guidelines.<sup>45</sup>

## 2.8 Statistical analyses

Analyses were performed in Matlab 2022a (Natick, Massachusetts). We used linear models to investigate the relationship between SN MRI markers, CSF biomarker level, and recognition memory. Using an ANCOVA, we also assessed the difference in SN volume and SN MRI contrast between diagnostic groups. We used the Statistical Parametric Mapping Toolbox 12 Revision 7771 (SPM) to calculate mass-univariate models to assess the relationship between



SN MRI contrast and volume and hippocampal novelty contrast, applying family-wise error (FWE) cluster-level correction for multiple comparisons. We limited our voxelwise analysis to a region defined by a hippocampal mask. In all analyses, we used scanner site, age, total intracranial volume (TIV), years of education, and sex as covariates. Linear associations were plotted using the Gramm toolbox for Matlab<sup>46</sup>, and group comparisons were drawn using the Raincloud toolbox.<sup>47</sup> We calculated Hedge's  $g$ ,<sup>48</sup> which is similar to Cohen's  $d$  but insensitive to group size differences, to calculate the effect sizes of the diagnostic group differences.

### 3 Results

A significant difference in SN volume between diagnostic groups was observed (ANCOVA;  $F(3,156)=4.13$ ,  $N=160$ ,  $p=0.001$ , Figure 2A). A subsequent Tukey-post-hoc test revealed that SN volume was lower in individuals with ADD compared to HC ( $p=0.003$ , 23% average volume difference) and compared to individuals with SCD ( $p=0.013$ , 28% average volume difference). SN volume of each HC ( $p=0.7$ ) and SCD ( $p=0.36$ ) did not differ from MCI SN volume. No significant difference in SN MRI contrast between diagnostic groups was observed ( $F(3,156)=0.23$ ,  $N=160$ ,  $p=0.89$ , Fig. 2B). We did not find an association between SN MRI contrast and SN volume ( $p=0.11$ ,  $r^2=0.07$ ,  $n=160$ ), indicating that the MRI measures are statistically independent. A one-way ANOVA revealed that SN volume ( $F(3,156)=3.05$ ,  $p=0.03$ ,  $N=160$ ) and SN MRI contrast differed between scanner sites ( $F(3,156) = 51.57$ ,  $p<0.001$ ,  $N=160$ ). Two-sided t-tests between the left and right SN volume and SN MRI contrast revealed a significantly higher SN volume ( $p<0.001$ ) and significantly higher SN MRI contrast ( $p=0.0092$ ) in the right compared to the left SN hemispheres. All tested associations are listed in supp. Table 1.

	HC	SCD	MCI	ADD
	<b>Whole dataset</b>			
<b>N</b>	79	53	18	10
<b>Age</b>	67.2 (5.1)	70.5 (6.1)**	71.72 (7)*	72.1 *(6.6)
<b>Sex (M: F)</b>	28:51	30:24	11:7	3:7
<b>SN volume[mm<sup>3</sup>]</b>	109.3 (25.6)	114 (27.5)	102.3 (27.3)	83.18 (17)**
<b>Years of education</b>	14.8 (2.67)	14.95 (3.04)	13.53 (2.92)	12.8 (2.7)

<b>MMSE</b>	29.35 (0.95)	29.02 (1.11)	27.82 (1.42)***	22.9 (2.92)***
<b>TIV [ml]</b>	1353.61 (205.53)	1405.38 (223.31)	1472 (259.05)	1445.56 (170.08)
<b>Subset with available CSF data</b>				
<b>N</b>	30	20	14	7
<b>CSF Ttau (pg/ml)</b>	322.1 (116.3)	346.3 (178.5)	614.1 (291.1)**	883.7 (502.2)***
<b>CSF Ptau (pg/ml)</b>	45.6 (13.9)	48.4	72.3 (32.9)*	106.6 (69.2)***
<b>CSF A<math>\beta</math>42/40 ratio</b>	0.1 (0.02)	0.1 (0.002)	0.006 (0.003)***	0.005 (0.02)***
<b>CSF A<math>\beta</math>42/Ptau181 ratio</b>	18.5 (5.5)	17.0 (4.4)	10.3 (8.0)**	5.8 (6.0)***

Table 1: Overview of the demographics, cognitive test results, and AD CSF pathology load in the sample analyzed in this work. Stars denote the P value of a two-sided t-test compared to HC: \*= $p < 0.05$ , \*\*= $p < 0.01$ , \*\*\*= $p < 0.0001$

### 3.1 SN volume is reduced in ADD but is not associated with CSF

#### A $\beta$ 42/40 and tau levels

-----Figure 2 approximately here-----

We performed a one-way ANOVA comparing diagnostic group differences in SN volume ( $F(3,156)=4.13$ ,  $N=160$ ,  $p=0.0056$ , Fig. 2A). A subsequent Tukey-post-hoc test revealed a lower SN volume in individuals with ADD compared to HC ( $p=0.003$ , Hedges'  $g=1.056$ ) and lower SN volume in individuals with ADD compared to individuals with SCD ( $p=0.013$ , Hedges'  $g=1.16$ ). There were no statistical differences in SN volume between HC and MCI (all  $p > 0.05$ ). The lack of statistical difference between HC and MCI indicates that SN volume decreases late into the disease progression. The significant effect size of  $g > 1^{48}$  for group differences between HC and ADD and the non-significant association between HC and MCI indicate a sharp decrease in SN volume with clinical ADD onset. A one-way ANOVA comparing SN MRI contrast between diagnostic groups revealed no significant difference between groups ( $F(3,156)=0.23$ ,  $N=160$ ,  $p=0.89$ , Fig. 2B). Overall, these results indicate that the SN shrinks but maintains a stable level of neuromelanin in individuals with ADD.

However, we did not find any association between SN volume and SN volume and the CSF biomarker levels (all  $p > 0.1$ , Fig. 2C-E).

### 3.2 Higher SN MRI contrast predicts higher voxel-wise hippocampal novelty contrast in A $\beta$ 42/40 positive individuals

To determine if SN MRI measures are related to changes in hippocampal activation during the presentation of novel stimuli, we calculated mass-univariate associations between SN volume, SN MRI contrast, and hippocampal novelty activation while correcting for site, age, sex, TIV, and years of education. These associations did not reveal any significant family-wise corrected- clusters. However, in A $\beta$ 42/40 positive individuals, SN MRI contrast was positively associated with the novelty contrast inside the hippocampus ( $p(\text{FWE})=0.002$ , 157 voxels,  $n=28$ , Table 2). These results are depicted in the horizontal (Fig. 3A) and sagittal (Fig. 3B) plane. We did not find this association in A $\beta$ 42/40 negative individuals.

The association between hippocampal novelty contrast and SN contrast in A $\beta$ 42/40 positive individuals was still observed after correcting for hippocampal volume ( $p(\text{FWE})=0.027$ , 89 voxels, Table 2) and diagnostic group ( $p(\text{FWE})=0.009$ , 152 voxels, Table 2), indicating that this finding was independent of hippocampal atrophy. This association was also observed in all individuals with known CSF biomarker status ( $p(\text{FWE})=0.018$ , 181 voxels,  $N=71$ , Supplementary Table. 2)

----- figure 3 approximately here -----

Cluster size	Cluster $p_{\text{FWE}}$	Peak T	Template x,y,z (mm)	Brain structures	Additional covariates
157	0.008	6.99	22 2 -18	Right anterior hippocampus	none
89	0.027	7.27	22 2 -17	Right anterior hippocampus	hippocampal volume

---

152	0.009	6.78	22 2 -18	Right anterior hippocampus	diagnostic group
-----	-------	------	----------	-------------------------------	---------------------

Table 2: SN MRI contrast correlates with novelty activation in a cluster in the right anterior hippocampus independent of diagnostic group and hippocampal volume

----- figure 4 approximately here -----

### **3.3 Higher SN volume predicts higher recognition memory and a higher global cognitive score**

A one-way ANOVA investigating diagnostic group differences in recognition memory ( $F(3,158)=19.5, p<0.001, N=160$ ) and Tukey post hoc tests revealed significantly lower recognition memory in ADD and MCI subjects compared to HC and SCD (all  $p<0.001$ , suppl. table S2).

As SN volume and recognition memory were decreased in individuals with ADD, we corrected for clinical group to assess for associations between SN MRI measures and recognition memory. We found a positive association between SN volume and recognition memory ( $N=160, p=0.017, r^2=0.11$ ) across groups. This finding remained significant after correcting for hippocampal volume ( $p=0.002, r^2=0.162$ ) and diagnostic group ( $p=0.023, r^2=0.231$ ), indicating this effect was independent of AD-driven degeneration.

To determine if the SN volume was related to overall cognitive function, we performed an additional analysis associating SN volume and contrast with a global cognitive score aggregated across five different cognitive domains (visuospatial abilities, memory, working memory, language, and executive function). SN volume was positively associated with the global cognitive score ( $p<0.0001, N=160, r^2=0.221$ , Fig. 3B). This association held after correcting for hippocampal volume ( $p<0.0001, N=160, r^2=0.175$ ) and diagnostic group ( $p=0.002, N=160, r^2=0.56$ ) indicating the association was not driven by AD. In addition to finding an association between SN volume and global cognition, we also found weak but significant correlations between SN volume and latent factors related to visual:  $p=0.007$ ,

$r^2=0.1$ , working memory:  $p=0.003$ ,  $r^2=0.125$ , language:  $p<0.001$ ,  $r^2=0.133$  and executive function:  $p<0.001$ ,  $r^2=0.136$ , suppl. Fig. 1). These results also remained significant after correcting for hippocampal volume (Visual:  $p=0.03$   $r^2=0.1$ , working memory:  $p=0.003$   $r^2=0.12$ , language:  $p=0.001$   $r^2=0.12735$ , executive function:  $p=0.001$ ,  $r^2=0.131$ ). These results indicate that higher SN volume was associated with recognition memory and cognitive ability across multiple domains and are independent of hippocampal atrophy in individuals across the ADD continuum.

## 4 Discussion

Using in vivo structural MRI measures of the SN (SN volume and MRI contrast), we assessed how SN the in ADD is affected in ADD and how the SN is related to hippocampal activity during novelty, subsequent recognition memory, and general cognition. In a subset of individuals with CSF biomarker data, we also assessed how SN degeneration is related to AD pathology. Our analyses revealed that SN MRI contrast and SN volume are statistically independent measures and that SN volume is lower in individuals with ADD compared to HC and individuals with SCD. However, SN volume did not differ between HC and MCI and was not associated with CSF biomarkers of AD pathology. While SN volume was associated with poorer recognition memory, SN MRI contrast was associated with hippocampal novelty in A $\beta$ 42/40 positive individuals but not in A $\beta$ 42/40 negative individuals. Finally, we found that SN volume was associated with a decline in recognition memory and global cognition in ADD but not with CSF measures of AD pathology.

We found no association between SN MRI contrast and SN volume. Previous studies have employed both SN MRI contrast and SN volume measures but did not clarify the relationship between them.<sup>49-52</sup> Our results indicate that they are statistically independent in the sample

tested. Postmortem literature suggests that SN MRI contrast correlates with the concentration of NM-rich cells in the SN,<sup>12</sup> and high SN MRI contrast spatially overlaps with clusters of cells producing tyrosine hydroxylase (TH).<sup>53</sup> However, other authors suggest that the MRI contrast might also be driven by water concentration,<sup>54</sup> indicating that the mechanisms underlying SN MRI contrast are still debated and not entirely understood. Several additional factors such as MRI contrast from blood vessels,<sup>55</sup> astrocytes,<sup>56</sup> myelinated axons,<sup>57</sup> and non-dopaminergic neurons<sup>58</sup> have been shown inside the SN and might also contribute to SN MRI contrast. Future studies are needed to investigate how SN-MRI contrast and SN volume are related to dopaminergic function and whether they can be used as statistically and functionally distinct indicators.

Our study revealed MRI-derived SN volume was 25% lower in ADD compared to HC. This decrease aligns with previous postmortem studies reporting varying degrees of SN volume reduction between a 10% and a 40% lower SN volume.<sup>24,59,60</sup> Also this study is the first to our knowledge, to report a reduction in SN volume in vivo. One study found no difference in SN volume<sup>26</sup>. Moreover, we found no SN volume decrease in MCI or SCD compared to HC, indicating that SN volume decreases occur at a later stage of ADD. These results indicate SN volume might be a sensitive in-vivo MRI marker to detect potential dopaminergic deficits in ADD. They pave the way for future longitudinal studies to assess how SN volume might be linked to changes in dopamine-dependent function across time. Interestingly, studies assessing group differences in NM-sensitive MRI contrast using TSE MRI sequences<sup>61,62</sup> also found no significant decrease in SN MRI contrast in ADD, in line with our results presented here.

In a subset of individuals with CSF biomarker status, we found no significant association between either SN MRI contrast or SN volume with AD pathology. Several postmortem studies also showed no association between SN cell loss and tau or amyloid pathology.<sup>25,28</sup> While one study<sup>27</sup> found an increase in tau in the SN together with increased SN degeneration in AD, they were not directly associated. However, we are the first to show this extends to CSF levels of AD pathology. Collectively, these findings indicate that SN degeneration may not be linked to the extent of tau or amyloid pathology. Previous reports show alpha-synuclein is related to SN degeneration in ADD. In one study alpha-synuclein was moderately associated with SN loss in ADD.<sup>28</sup> Alpha-synuclein is toxic to the SN pars compacta,<sup>63</sup> notably in Parkinson's disease.<sup>64</sup> Additionally, elevated alpha-synuclein levels have consistently been demonstrated in individuals with MCI and ADD.<sup>27,65-68</sup> Therefore, the SN degeneration observed in our study may be related to elevated alpha-synuclein levels. While alpha-synuclein was not assessed in DELCODE, it will be important in future studies to investigate to what extent alpha-synuclein pathology is related to SN degeneration in ADD. The results presented here indicate amyloid and tau-independent mechanisms may contribute to SN degeneration in ADD.

Previous studies revealed an inverted U-shaped association between A $\beta$ 42/40 CSF levels and hippocampal activity during the novelty recognition task analyzed here,<sup>32</sup> indicating that A $\beta$ 42/40-positive individuals have lower hippocampal activity in later clinical stages (MCI, dementia). Additionally, CSF tau levels are only associated with hippocampal novelty activation in A $\beta$ 42/40-positive individuals.<sup>69</sup> We show here that SN MRI contrast is only associated with hippocampal novelty contrast in A $\beta$ 42/40 positive individuals. Should higher

SN contrast predict higher dopaminergic output,<sup>12</sup> this would indicate that in individuals with decreased baseline hippocampal novelty activity, higher SN dopaminergic release might act as a compensatory mechanism to restore hippocampal novelty activation in individuals with high levels of amyloid. Alternatively, a decrease in SN volume and a decreased baseline hippocampal novelty activity are sufficient to decrease hippocampal novelty activity significantly. Higher SN MRI contrast,<sup>4</sup> higher SN/VTA MRI activity,<sup>7,70-75</sup> and higher cellular SN activity<sup>5</sup> predict better long-term memory. We extend these previous findings by showing that SN volume is related to memory decline in individuals spanning the AD continuum. We also expand previous findings showing that the SN is linked to broader cognitive functions such as cognitive control<sup>2,17</sup> by showing that it is related to several factor scores spanning five cognitive domains and global cognition. Future studies should assess how SN volume is related to other dopaminergic functions such as working memory<sup>76</sup> and reward.<sup>77</sup>

It is important to note several limitations on interpretation of these findings. The number of individuals with ADD was low, thus the results presented here need to be replicated in larger samples. The contribution of VTA degeneration, another source of dopamine in the brain, in ADD,<sup>78</sup> to novelty and memory deficits remain to be investigated. Our SN segmentations were performed semi-automatically, possibly introducing bias and an SN overestimation. Finally, our study was cross-sectional, longitudinal follow-up data, once available, will enable us to explore how SN degeneration is related to cognitive function over time.

Future studies should attempt to replicate our results in larger cohorts of individuals with ADD with AD pathology CSF levels. They should also assess how SN contrast and SN volume are structurally and functionally related and to what extent they serve as independent



in-vivo SN MRI markers. Further investigation is required to assess whether SN volume, as previously observed for SN MRI contrast, is related to other dopamine-dependent functions. Finally, further research is required to systematically assess the exact mechanisms underlying SN degeneration in ADD, e.g. with respect to the contribution of alpha-synuclein.

In conclusion, we show in-vivo SN markers are differentially related to hippocampal activity during novelty and recognition memory decline in ADD. SN degeneration is independent of CSF biomarkers of AD pathology, opening avenues for longitudinal assessments of tau- and A $\beta$ 42/40 independent mechanisms of SN degeneration in ADD.

## Figure legends

**Figure 1 fMRI task and SN template:** (A) Subjects were presented with 88 novel scenes interleaved with two pre-familiarized scenes, and they were instructed to label the images as inside or outside. 70 min later, they rated the 88 previously presented images and 44 novel images by their familiarity in front of a computer. (B) We generated a template image from 188 FLASH images using ANTs, from which the SN was segmented manually and morphed into subject space. (C) A pons mask (in yellow) was segmented in template space and morphed into native space for SN intensity normalization.

**Figure 2 SN volume is lower in ADD but is not associated with AD pathology:** (A) An ANCOVA between SN volume and diagnostic groups and a subsequent posthoc tests revealed a significantly lower SN volume in individuals with ADD compared to HC and SCD ( $F(3,156)=4.13$ ,  $N=160$ ,  $p=0.0056$ ). (B) An ANCOVA between SN MRI contrast and diagnostic groups revealed no significant difference ( $F(3,156)=0.23$ ,  $N=160$ ,  $p=0.89$ ). (C) No significant association between SN MRI measures and A $\beta$ 42/40 ratio (C, E) or total tau (D, F) was observed ( $n=71$ ).

**Figure 3: Higher SN MRI contrast predicts higher hippocampal novelty contrast in A $\beta$ 42/40 – positive individuals:** (A) Using mass univariate linear models, we identified an

association between SN MRI contrast and a cluster in the anterior right hippocampus. Activation is zoomed in on the hippocampus in a 40x40 voxel window. **(B)** The same hippocampal cluster as in **(A)** is shown in the sagittal plane. Note that ‘T’ denotes each voxel’s T value statistics.

**Figure 4: Linear regression models regressing SN volume and each recognition memory and global cognition were significant: (A)** SN volume predicted better recognition memory (N=160,  $p=0.017$ ,  $r^2=0.11$ ). **(B)** Higher SN volume predicted better global cognition.  $p=0.0001$ , N=160,  $r^2=0.221$ )

**Figure S1: Higher SN volume predicts higher values of all factor scores after correcting for site, years of education, sex, and age: (A)** SN volume correlates with visuospatial abilities ( $p=0.0007$ ,  $n=160$ ,  $r^2=0.281$ ) **(B)** SN volume correlates with memory ( $p=0.007$ ,  $n=160$ ,  $r^2=0.1$ ) **(C)** SN volume correlates with working memory ( $p=0.007$ ,  $n=160$ ,  $r^2=0.328$ ) **(D)** SN volume correlates with executive function ( $p<0.001$ ,  $n=160$ ,  $r^2=0.387$ ) **(E)** SN volume correlates with language ( $p<0.001$ ,  $n=160$ ,  $r^2=0.397$ )

## Data availability

Data, study protocol, and biomaterials can be shared with partners based on individual data and biomaterial transfer agreements.

## Acknowledgments

The authors would like to thank all study participants for their invaluable contributions.

## Funding

The study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen; DZNE), reference number BN012.

F.K is supported by the German Federal Ministry of Education and Research (BMBF, funding code 01ED2102B) under the aegis of the EU Joint Programme – Neurodegenerative Disease Research (JPND). He is paid from a stipend awarded by the medical faculty in Magdeburg.

E.D. and M.B. are supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Project-ID 425899996—SFB 1436

### **Competing interests**

The authors declare no conflicts of interest.

## Supplementary figures

-----Figure S1 approximately here-----

regressor\Predictor	SN MRI contrast	SN volume
<b>SN MRI measures</b>		
SN volume	p=0.007, r <sup>2</sup> =0.2	-
<b>Covariates</b>		
Sex	t(160)=1.0918 ,p=0.277 p=0.007, r <sup>2</sup> =0.2	t(160)=-1.58 ,p=0.116 -
Age	<b>p=0.047771 r<sup>2</sup>=0.49555</b>	p=0.1 r <sup>2</sup> =0.07
Years of education	p=0.54985 r <sup>2</sup> =0.49555	p=0.11942 r <sup>2</sup> =0.074473
<b>ANOVAs/ttests</b>		
Diagnostic group	F(159)=0.22673 p=1	<b>F(159)=4.3586 p&lt;0.0001</b>
Site	<b>F(159)=51, p=0</b>	<b>F(159)=3.1, p=0.03</b>
left/right	<b>t(318)=-2.62, p=0.0092</b>	<b>t(318)=5.6, p&lt;0.0001</b>
<b>CSF measures</b>		
total tau	p=0.83094 r <sup>2</sup> =0.55004'	p=0.93444 r <sup>2</sup> =0.095821
Aβ <sub>42</sub> /40 ratio	p=0.55205 r <sup>2</sup> =0.55226	p=0.40148 r <sup>2</sup> =0.10585
phosphotau	p=0.68495 r <sup>2</sup> =0.5509	p=0.91621 r <sup>2</sup> =0.095883
<b>Cognitive parameters</b>		
recognition memory (all)	p=0.9946 r <sup>2</sup> =0.51203	<b>p=0.017358 r<sup>2</sup>=0.11395</b>
Recognition memory (HC)	p=0.90329 r <sup>2</sup> =0.63084	<b>p=0.017905 r<sup>2</sup>=0.21098</b>
Recognition memory (SCD)	p=0.64624 r <sup>2</sup> =0.41908	p=0.81318 r <sup>2</sup> =-0.053143
Recognition memory (MCI)	p=0.26635 r <sup>2</sup> =0.56645	p=0.96855 r <sup>2</sup> =0.24363
Recognition memory (ADD)	p=0.68243, r <sup>2</sup> =0.83555	p=0.99354, r <sup>2</sup> =0.38693
Global cognition (all)	p=0.9946 r <sup>2</sup> =0.51203	<b>p=0.017358 r<sup>2</sup>=0.11395</b>
Global cognition (HC)	p=0.90512 r <sup>2</sup> =0.14581	<b>p=0.017905 r<sup>2</sup>=0.21098</b>
Global cognition (SCD)	p=0.71901 r <sup>2</sup> =-0.05144	p=0.81318 r <sup>2</sup> =-0.053143
Global cognition (MCI)	p=0.24318 r <sup>2</sup> =0.39117	p=0.96855 r <sup>2</sup> =0.24363
Global cognition (ADD)	p=0.9683, r <sup>2</sup> =0.42696	p=0.9953 r <sup>2</sup> =0.3216
Visuospatial factor	<b>p=0.024664 r<sup>2</sup>=0.50896</b>	<b>p=0.028853 r<sup>2</sup>=0.09745</b>
Working memory Factor	p=0.093165 r <sup>2</sup> =0.50163	<b>p=0.0029906 r<sup>2</sup>=0.12134</b>
Memory Factor	p=0.73847 r <sup>2</sup> =0.49259	<b>p=0.049431 r<sup>2</sup>=0.091739</b>
Language Factor	p=0.34736 r <sup>2</sup> =0.49518	<b>p=0.0017029 r<sup>2</sup>=0.12735</b>
Executive function	p=0.091937 r <sup>2</sup> =0.5017	<b>p=0.0013274 r<sup>2</sup>=0.13001</b>
Hippocampal Novelty contrast (CSF subset)	p(FWE)=0.01, 243 voxels, N=71	p>0.001
Hippocampal novelty contrast (abeta positive)	(p(FWE)=0.02, 190 voxels, N=28)	p>0.001

**Table S1:** Overview of all tested linear correlations with years of education, age, sex, and scanner site as covariates,  $r^2$  indicates Pearson correlation coefficient. Significant correlations are highlighted in bold.

Cluster size	Cluster $p_{FWE}$	Cluster $p_{uncorrected}$	Peak T	Template x,y,z (mm)	Brain structures
582	0.059	0.001	4.03	44 -44 -24	Right anterior
			3.8	40 -47 29	hippocampus
			3.28	35 -45 -27	
190	0.78	0.002	7.18	22 2 -18	Right anterior hippocampus

Table S2: In a subset enriched with CSF data, SN MRI contrast correlates with novelty activation in 2 clusters in the right anterior hippocampus

dependent variable	Statistics
<b>CSF measures</b>	
total tau	F(3,67)=14.81 p<0.0001, N=71
A $\beta$ 42/40 ratio	F(3,67)=11.87 p<0.0001, N=71
phosphotau	F(3,67)=10.81 p<0.0001, N=71
<b>Cognitive parameters</b>	
recognition memory	F(3,156)=19.5 p<0.001, N=160
Global cognition	F(3,156)=59.73 p<0.0001, N=160
Visual factor	F(3,156)=28.24 p<0.0001, N=160
Working memory Factor	F(3,156)=31.14 p<0.0001, N=160
Memory Factor	F(3,156)=85.06 p<0.0001, N=160
Language Factor	F(3,156)=69.56 p<0.0001, N=160

Table S3: ANOVA F score results for diagnostic group differences for all relevant CSF and cognitive measures

## Funding

The study was funded by the German Center for Neurodegenerative Diseases [Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)], reference number BN012, the European Union's Horizon 2020 Research and Innovation Programme under Grants 785907 (HBP SGA2) and 945539 (HBP SGA3), and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Project-ID 425899996 – SFB 1436.

---

## References

1. DeLong MR, Crutcher MD, Georgopoulos AP. Relations between movement and single cell discharge in the substantia nigra of the behaving monkey. *Journal of Neuroscience*. 1983;3(8):1599-1606. doi:10.1523/jneurosci.03-08-01599.1983
2. Boehler CN, Bunzeck N, Krebs RM, et al. Substantia nigra activity level predicts trial-to-trial adjustments in cognitive control. *J Cogn Neurosci*. 2011;23(2):362-373. doi:10.1162/jocn.2010.21473
3. Bellissimo MI, Kouzmine I, Ferro MM, De Oliveira BH, Canteras NS, Da Cunha C. Is the unilateral lesion of the left substantia nigra pars compacta sufficient to induce working memory impairment in rats? *Neurobiol Learn Mem*. 2004;82(2):150-158. doi:10.1016/j.nlm.2004.06.006
4. Düzel S, Schütze H, Stallforth S, et al. A close relationship between verbal memory and SN/VTA integrity in young and older adults. *Neuropsychologia*. 2008;46(13):3042-3052. doi:10.1016/j.neuropsychologia.2008.06.001
5. Kamiński J, Mamelak AN, Birch K, Mosher CP, Tagliati M, Rutishauser U. Novelty-Sensitive Dopaminergic Neurons in the Human Substantia Nigra Predict Success of Declarative Memory Formation. *Current Biology*. 2018;28(9):1333-1343.e4. doi:10.1016/j.cub.2018.03.024
6. Mikell CB, Sheehy JP, Youngerman BE, et al. Features and timing of the response of single neurons to novelty in the substantia nigra. *Brain Res*. 2014;1542:79-84. doi:10.1016/j.brainres.2013.10.033
7. Bunzeck N, Düzel E. Absolute Coding of Stimulus Novelty in the Human Substantia Nigra/VTA. *Neuron*. 2006;51(3):369-379. doi:10.1016/j.neuron.2006.06.021

- 
8. Kumaran D, Maguire EA. The dynamics of hippocampal activation during encoding of overlapping sequences. *Neuron*. 2006;49(4):617-629. doi:10.1016/j.neuron.2005.12.024
  9. Strange BA, Dolan RJ.  $\beta$ -Adrenergic modulation of emotional memory-evoked human amygdala and hippocampal responses. *Proc Natl Acad Sci U S A*. 2004;101(31):11454-11458. doi:10.1073/pnas.0404282101
  10. Lisman J, Grace AA, Duzel E. A neoHebbian framework for episodic memory; role of dopamine-dependent late LTP. *Trends Neurosci*. 2011;34(10):536-547. doi:10.1016/j.tins.2011.07.006
  11. Takeuchi T, Duzkiewicz AJ, Sonneborn A, et al. Locus coeruleus and dopaminergic consolidation of everyday memory. *Nature*. 2016;537(7620):357-362. doi:10.1038/nature19325
  12. Cassidy CM, Zucca FA, Girgis RR, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. *Proc Natl Acad Sci U S A*. 2019;116(11):5108-5117. doi:10.1073/pnas.1807983116
  13. Sulzer D, Cassidy C, Horga G, et al. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. *NPJ Parkinsons Dis*. 2018;4(1). doi:10.1038/s41531-018-0047-3
  14. Liu W, Wang C, He T, et al. Substantia nigra integrity correlates with sequential working memory in Parkinson's disease. *Journal of Neuroscience*. 2021;41(29):6304-6313. doi:10.1523/JNEUROSCI.0242-21.2021
  15. Vitali P, Pan MI, Palesi F, et al. Substantia Nigra Volumetry with 3-T MRI in de Novo and Advanced Parkinson Disease. *Radiology*. 2020;296(2):401-410. doi:10.1148/radiol.2020191235

- 
16. Zucca FA, Bellei C, Giannelli S, et al. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: Consequences for neuronal vulnerability. *J Neural Transm*. 2006;113(6):757-767. doi:10.1007/s00702-006-0453-2
  17. Chowdhury R, Guitart-masip M, Lambert C, Dolan RJ, Düzel E. Structural integrity of the substantia nigra and subthalamic nucleus predicts flexibility of instrumental learning in older-age individuals. *Neurobiol Aging*. 2013;34(10):2261-2270. doi:10.1016/j.neurobiolaging.2013.03.030
  18. Dahl MJ, Bachman SL, Dutt S, et al. The integrity of dopaminergic and noradrenergic brain regions is associated with different aspects of late-life memory performance. *Nat Aging*. 2023;3(9):1128-1143. doi:10.1038/s43587-023-00469-z
  19. Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. *Neuroreport*. 2006;17(11):1215-1218. doi:10.1097/01.wnr.0000227984.84927.a7
  20. Castellani RJ, Peclovits A, Perry G. *Neuropathology of Alzheimer's Disease*. Elsevier Inc.; 2014. doi:10.1016/B978-0-12-386456-7.04604-9
  21. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's and Dementia*. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
  22. Pan X, Kaminga AC, Wen SW, Wu X, Acheampong K, Liu A. Dopamine and dopamine receptors in Alzheimer's disease: A systematic review and network meta-analysis. *Front Aging Neurosci*. 2019;10(JUL). doi:10.3389/fnagi.2019.00175
  23. Gibb WRG, Mountjoy CQ, Mann DMA, Lees AJ. The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. *J Neurol Neurosurg Psychiatry*. 1989;52(2):193-200. doi:10.1136/jnnp.52.2.193



- 
24. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. *Arch Neurol*. 2003;60(3):337-341. doi:10.1001/archneur.60.3.337
  25. Kazee AM, Cox C, Richfield EK. Substantia nigra lesions in Alzheimer disease and normal aging. *Alzheimer Dis Assoc Disord*. 1995;9(2):61-67. doi:10.1097/00002093-199509020-00001
  26. Reyes MG, Faraldi F, Rydman R, Wang CC. Decreased nigral neuromelanin in Alzheimer's disease. *Neurol Res*. 2003;25(2):179-182. doi:10.1179/016164103101201166
  27. Attems J, Quass M, Jellinger KA. Tau and  $\alpha$ -synuclein brainstem pathology in Alzheimer disease: Relation with extrapyramidal signs. *Acta Neuropathol*. 2007;113(1):53-62. doi:10.1007/s00401-006-0146-9
  28. Burns JM, Galvin JE, Roe CM, Morris JC, McKeel DW. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. *Neurology*. 2005;64(8):1397-1403. doi:10.1212/01.WNL.0000158423.05224.7F
  29. Schneider JA, Bienias JL, Gilley DW, Kvarnberg DE, Mufson EJ, Bennett DA. Improved detection of substantia nigra pathology in Alzheimer's disease. *Journal of Histochemistry and Cytochemistry*. 2002;50(1):99-106. doi:10.1177/002215540205000111
  30. Uematsu M, Nakamura A, Ebashi M, Hirokawa K, Takahashi R, Uchihara T. Brainstem tau pathology in Alzheimer's disease is characterized by increase of three repeat tau and independent of amyloid  $\beta$ . *Acta Neuropathol Commun*. 2018;6(1):1. doi:10.1186/s40478-017-0501-1
  31. Daffner KR, Rentz DM, Faust R, Budson AE, Holcomb PJ. Pathophysiology underlying diminished. *Neurology*. 2001;01378:1377-1383.

- 
32. Billette O V., Ziegler G, Aruci M, et al. Novelty-Related fMRI Responses of Precuneus and Medial Temporal Regions in Individuals at Risk for Alzheimer Disease. *Neurology*. 2022;99(8):e775-e788. doi:10.1212/WNL.0000000000200667
  33. Moulin CJA, Perfect TJ, Jones RW. Evidence for intact memory monitoring in Alzheimer's disease: Metamemory sensitivity at encoding. *Neuropsychologia*. 2000;38(9):1242-1250. doi:10.1016/S0028-3932(00)00037-3
  34. Vitali P, Minati L, Chiarenza G, et al. The Von Restorff effect in ageing and Alzheimer's disease. *Neurological Sciences*. 2006;27(3):166-172. doi:10.1007/s10072-006-0662-3
  35. Jessen F, Amariglio RE, Van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimer's and Dementia*. 2014;10(6):844-852. doi:10.1016/j.jalz.2014.01.001
  36. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008
  37. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005
  38. Jessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). *Alzheimers Res Ther*. 2018;10(1):1-10. doi:10.1186/s13195-017-0314-2

- 
39. Betts MJ, Cardenas-Blanco A, Kanowski M, Jessen F, Düzel E. In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults. *Neuroimage*. 2017;163:150-159. doi:10.1016/j.neuroimage.2017.09.042
  40. Düzel E, Schütze H, Yonelinas AP, Heinze HJ. Functional phenotyping of successful aging in long-term memory: Preserved performance in the absence of neural compensation. *Hippocampus*. 2010;814:n/a-n/a. doi:10.1002/hipo.20834
  41. Düzel E, Berron D, Schütze H, et al. CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2018;10:782-790. doi:10.1016/j.dadm.2018.10.003
  42. Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. *Neuroimage*. 2011;54(3):2033-2044. doi:10.1016/j.neuroimage.2010.09.025
  43. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. *Neuron*. 2002;33(3):341-355. doi:10.1016/S0896-6273(02)00569-X
  44. Wolfsgruber S, Kleineidam L, Guski J, et al. Minor neuropsychological deficits in patients with subjective cognitive decline. *Neurology*. 2020;95(9):E1134-E1143. doi:10.1212/WNL.0000000000010142
  45. Jessen F, Wolfsgruber S, Kleineidam L, et al. Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. *Alzheimer's and Dementia*. 2023;19(2):487-497. doi:10.1002/alz.12674
  46. Morel P. Grammar: grammar of graphics plotting in Matlab. *The Journal of Open Source Software*. 2018;3(23):568. doi:10.21105/joss.00568

- 
47. Allen M, Poggiali D, Whitaker K, Marshall TR, Kievit RA. Raincloud plots: A multi-platform tool for robust data visualization [version 1; peer review: 2 approved]. *Wellcome Open Res.* 2019;4:1-52. doi:10.12688/wellcomeopenres.15191.1
  48. Hedges L V. Distribution Theory for Glass's Estimator of Effect Size and Related Estimators. *Journal of Educational Statistics.* 1981;6(2):107. doi:10.2307/1164588
  49. Al Haddad R, Chamoun M, Tardif CL, et al. Normative Values of Neuromelanin-Sensitive MRI Signal in Older Adults Obtained Using a Turbo Spin Echo Sequence. *Journal of Magnetic Resonance Imaging.* 2023;58(1):294-300. doi:10.1002/jmri.28530
  50. Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B. Ageing of substantia nigra in humans: Cell loss may be compensated by hypertrophy. *Neuropathol Appl Neurobiol.* 2002;28(4):283-291. doi:10.1046/j.1365-2990.2002.00393.x
  51. Langley J, Hussain S, Flores JJ, Bennett IJ, Hu X. Characterization of age-related microstructural changes in locus coeruleus and substantia nigra pars compacta. *Neurobiol Aging.* 2020;87:89-97. doi:10.1016/j.neurobiolaging.2019.11.016
  52. Xing Y, Sapuan A, Dineen RA, Auer DP. Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. *Movement Disorders.* 2018;33(11):1792-1799. doi:10.1002/mds.27502
  53. Keren NI, Taheri S, Vazey EM, et al. Histologic validation of locus coeruleus MRI contrast in post-mortem tissue. *Neuroimage.* 2015;113:235-245. doi:10.1016/j.neuroimage.2015.03.020
  54. Watanabe T, Wang X, Tan Z, Frahm J. Magnetic resonance imaging of brain cell water. *Sci Rep.* 2019;9(1):1-14. doi:10.1038/s41598-019-41587-2



- 
55. Balzano T, del Rey NLG, Esteban-García N, et al. Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates. *NPJ Parkinsons Dis.* 2024;10(1):1-11. doi:10.1038/s41531-024-00735-w
  56. Bondi H, Chiazza F, Masante I, Bortolotto V, Canonico PL, Grilli M. Heterogenous response to aging of astrocytes in murine Substantia Nigra pars compacta and pars reticulata. *Neurobiol Aging.* 2023;123:23-34. doi:10.1016/j.neurobiolaging.2022.12.010
  57. Walker CK, Roche JK, Sinha V, Roberts RC. Substantia nigra ultrastructural pathology in schizophrenia. *Schizophr Res.* 2018;197(3):209-218. doi:10.1016/j.schres.2017.12.004
  58. Hebb MO, Robertson HA. Identification of a subpopulation of substantia nigra pars compacta  $\gamma$ -aminobutyric acid neurons that is regulated by basal ganglia activity. *Journal of Comparative Neurology.* 1999;416(1):30-44. doi:10.1002/(SICI)1096-9861(20000103)416:1<30::AID-CNE4>3.0.CO;2-2
  59. Tabaton M, Schenone A, Romagnoli P, Mancardi GL. A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer's disease. *Acta Neuropathol.* 1985;68(3):218-223. doi:10.1007/BF00690198
  60. Forstl H, Levy R, Burns A, Luthert P, Cairns N. Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease - A hypothesis. *Pharmacopsychiatry.* 1994;27(1):11-15. doi:10.1055/s-2007-1014267
  61. Chen X, Huddleston DE, Langley J, et al. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. *Magn Reson Imaging.* 2014;32(10):1301-1306. doi:10.1016/j.mri.2014.07.003




- 
62. Moon WJ, Park JY, Yun WS, et al. A comparison of substantia nigra T1 hyperintensity in parkinson's disease dementia, alzheimer's disease and age-matched controls: Volumetric analysis of neuromelanin imaging. *Korean J Radiol.* 2016;17(5):633-640. doi:10.3348/kjr.2016.17.5.633
  63. Ghiglieri V, Calabrese V, Calabresi P. Alpha-synuclein: From early synaptic dysfunction to neurodegeneration. *Front Neurol.* 2018;9(MAY). doi:10.3389/fneur.2018.00295
  64. Kanaan NM, Manfredsson FP. Loss of Functional Alpha-Synuclein: A Toxic Event in Parkinson's Disease? *J Parkinsons Dis.* 2012;2(4):249-267. doi:10.3233/JPD-012138
  65. Jellinger KA. Neuropathology of the Alzheimer's continuum: an update. *Free Neuropathol.* 2020;1:1-34. doi:10.17879/freeneuropathology-2020-3050
  66. Jellinger KA.  $\alpha$ -Synuclein pathology in Parkinson's and Alzheimer's disease brain: Incidence and topographic distribution - A pilot study. *Acta Neuropathol.* 2003;106(3):191-202. doi:10.1007/s00401-003-0725-y
  67. Korff A, Liu C, Ghingina C, Shi M, Zhang J.  $\alpha$ -synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. *Journal of Alzheimer's Disease.* 2013;36(4):679-688. doi:10.3233/JAD-130458
  68. Twohig D, Nielsen HM.  $\alpha$ -synuclein in the pathophysiology of Alzheimer's disease. *Mol Neurodegener.* 2019;14(1):1-19. doi:10.1186/s13024-019-0320-x
  69. Düzel E, Ziegler G, Berron D, et al. Amyloid pathology but not APOE  $\epsilon$ 4 status is permissive for tau-related hippocampal dysfunction. *Brain.* 2022;145(4):1473-1485. doi:10.1093/brain/awab405
  70. Schott BH, Sellner DB, Lauer CJ, et al. Activation of midbrain structures by associative novelty and the formation of explicit memory in humans. *Learning and Memory.* 2004;11(4):383-387. doi:10.1101/lm.75004



- 
71. Ripollés P, Marco-Pallarés J, Alicart H, Tempelmann C, Rodríguez-Fornells A, Noesselt T. Intrinsic monitoring of learning success facilitates memory encoding via the activation of the SN/VTA-hippocampal loop. *Elife*. 2016;5(September):1-35. doi:10.7554/eLife.17441
  72. Koster R, Guitart-Masip M, Dolan RJ, Düzel E. Basal ganglia activity mirrors a benefit of action and reward on long-lasting event memory. *Cerebral Cortex*. 2015;25(12):4908-4917. doi:10.1093/cercor/bhv216
  73. Kafkas A, Montaldi D. Striatal and midbrain connectivity with the hippocampus selectively boosts memory for contextual novelty. *Hippocampus*. 2015;25(11):1262-1273. doi:10.1002/hipo.22434
  74. Loh E, Kumaran D, Koster R, Berron D, Dolan R, Düzel E. Context-specific activation of hippocampus and SN/VTA by reward is related to enhanced long-term memory for embedded objects. *Neurobiol Learn Mem*. 2016;134(Part A):65-77. doi:10.1016/j.nlm.2015.11.018
  75. Krebs RM, Schott BH, Düzel E. Personality Traits Are Differentially Associated with Patterns of Reward and Novelty Processing in the Human Substantia Nigra/Ventral Tegmental Area. *Biol Psychiatry*. 2009;65(2):103-110. doi:10.1016/j.biopsych.2008.08.019
  76. Xu J, Guan X, Wen J, Wang T, Zhang M, Xu X. Substantia nigra iron affects functional connectivity networks modifying working memory performance in younger adults. *European Journal of Neuroscience*. 2021;54(11):7959-7973. doi:10.1111/ejn.15532
  77. Zaghoul KA, Blanco JA, Weidemann CT, et al. Human substantia nigra neurons encode unexpected financial rewards. *Science (1979)*. 2009;323(5920):1496-1499. doi:10.1126/science.1167342



78. Bozzali M, D'Amelio M, Serra L. Ventral tegmental area disruption in Alzheimer's disease. *Aging*. 2019;11(5):1325-1326. doi:10.18632/aging.101852



**A****B**





**A****B**

6

5

4

3

2

1

0

**T**